One of the few conditions with an approved cannabis medicine — and an honest ceiling on what it does.
Approval rests on randomized trials in patients whose spasticity did not respond to standard treatment. A meaningful minority respond well — early-response designs show roughly a third reach the responder threshold.
Nabiximols MS trials — PubMed ↗Across MS trials, patient-reported spasticity and pain improvements are consistently larger than objective spasm measurements. Both numbers are real; they measure different things.
Subjective vs objective spasticity — PubMed ↗The large CUPID trial tested whether THC could slow disease progression and found no meaningful effect. Symptom relief, yes; modifying the disease, no — a distinction that matters enormously for treatment decisions.
CUPID progression trial — PubMed ↗Secondary trial outcomes and observational data suggest improvements in bladder urgency and sleep quality in MS patients using cannabinoids. Plausible and patient-valued, but these are secondary endpoints, not primary evidence.
Cannabinoids MS bladder sleep — PubMed ↗Nabiximols (Sativex), a 1:1 THC:CBD oromucosal spray, is approved across Europe, Canada and elsewhere for multiple-sclerosis spasticity that resists standard treatment. Trials show real but modest responder rates — it helps a subset of patients, not everyone.
Medical Evidence STRONG EVIDENCEDronabinol and nabilone (synthetic THC) are approved for chemo nausea and AIDS wasting; nabiximols (THC+CBD spray) is approved for MS spasticity in 25+ countries; Epidiolex (CBD) for severe epilepsy. The medical channel exists and works — it is simply narrower than the dispensary menu suggests.
Medical Evidence STRONG EVIDENCEThe landmark 2017 National Academies report — the most rigorous evidence review to date — found substantial evidence for only three indications: chronic pain in adults, chemotherapy-induced nausea (oral cannabinoids), and MS-related spasticity. Nearly everything else sits at "limited" or "insufficient."
Medical Evidence STRONG EVIDENCETHC partially activates CB1 receptors rather than fully switching them on. This partial activity is one reason cannabis has a wide safety margin compared to full-agonist synthetic cannabinoids ("spice"), which can be lethal — a critical distinction often lost in public debate.
THCCannabis is not an approved treatment for multiple sclerosis in most jurisdictions, and nothing here recommends using it. If multiple sclerosis affects your life, bring this research — literally, these sources — to a physician and decide together. Laws differ by country and state; check CannabisLaws.ai before anything else.